SCI

9 September 2024

Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity

(Trends in cancer;IF:14.3)

  • Redin E, Quintanal-Villalonga Á, Rudin CM. Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity. Trends Cancer. 2024 Aug 19:S2405-8033(24)00156-0. doi: 10.1016/j.trecan.2024.07.008. Epub ahead of print. PMID: 39164163.

  • Correspondence: Esther Redin, Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA Charles M. Rudin, Pharmacology Program, Weill Cornell Medicine, New York, NY 10065, USA

    email:redinre@mskcc.org (E. Redin) and rudinc@mskcc.org (C.M. Rudin).

Abstract 摘要

Small cell lung cancer (SCLC) is a devastating disease with high proliferative and metastatic capacity. SCLC has been classified into molecular subtypes based on differential expression of lineage-defining transcription factors. Recent studies have proposed new subtypes that are based on both tumor-intrinsic and -extrinsic factors. SCLC demonstrates substantial intratumoral subtype heterogeneity characterized by highly plastic transcriptional states, indicating that the initially dominant subtype can shift during disease progression and in association with resistance to therapy. Strategies to promote or constrain plasticity and cell fate transitions have nominated novel targets that could prompt the development of more durably effective therapies for patients with SCLC. In this review, we describe the latest advances in SCLC subtype classification and their biological and clinical implications.

小细胞肺癌(SCLC)是一种具有高度增殖和转移能力的毁灭性疾病。SCLC已基于谱系决定性转录因子的差异表达被分为分子亚型。最近的研究提出了基于肿瘤内在和外在因素的新亚型。SCLC表现出显著的肿瘤内亚型异质性,其特征是具有高度可塑性的转录状态,表明最初占主导地位的亚型可以在疾病进展过程中发生变化,并与治疗耐药性相关。促进或限制可塑性和细胞命运转换的策略提出了新的靶点,这些靶点可能促使开发出更持久有效的治疗方案来帮助SCLC患者。在本综述中,我们介绍了SCLC亚型分类的最新进展及其生物学和临床意义。